AtriCure Company Profile (NASDAQ:ATRC)

About AtriCure

AtriCure logoAtriCure, Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company's segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. Its Isolator Synergy System, which includes its Isolator Synergy clamps, radio frequency (RF) generator and related switchbox, provides treatment for persistent and long-standing persistent Afib concomitant. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: ATRC
  • CUSIP: 04963C20
Key Metrics:
  • Previous Close: $17.49
  • 50 Day Moving Average: $16.799
  • 200 Day Moving Average: $16.976
  • 52-Week Range: $13.44 - $20.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.98
  • P/E Growth: -0.800
  • Market Cap: $577.86M
  • Outstanding Shares: 33,239,000
  • Beta: 0.54
  • Net Margins: -23.78%
  • Return on Equity: -19.84%
  • Return on Assets: -13.01%
  • Debt-to-Equity Ratio: 0.22%
  • Current Ratio: 3.19%
  • Quick Ratio: 2.47%
Additional Links:
Companies Related to AtriCure:

Analyst Ratings

Consensus Ratings for AtriCure (NASDAQ:ATRC) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.57 (18.33% upside)

Analysts' Ratings History for AtriCure (NASDAQ:ATRC)
DateFirmActionRatingPrice TargetDetails
2/6/2017Canaccord GenuityReiterated RatingBuy$20.00View Rating Details
8/10/2016BTIG ResearchReiterated RatingBuy$34.00 -> $19.00View Rating Details
8/8/2016Needham & Company LLCReiterated RatingBuy$23.00 -> $20.00View Rating Details
8/8/2016Piper Jaffray CompaniesReiterated RatingOverweight$22.00 -> $17.00View Rating Details
8/6/2016JMP SecuritiesSet Price TargetBuy$23.00View Rating Details
8/5/2016Stifel NicolausLower Price TargetBuy$26.00 -> $21.00View Rating Details
3/29/2016Northland SecuritiesInitiated CoverageOutperform$24.00View Rating Details
10/6/2015Leerink SwannReiterated RatingBuyView Rating Details
7/28/2015Dougherty & CoBoost Price TargetBuy$25.00 -> $30.00View Rating Details
(Data available from 2/20/2015 forward)


Earnings History for AtriCure (NASDAQ:ATRC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017ListenView Earnings Details
10/27/2016Q316($0.28)($0.21)$10.75 million$38.34 millionViewListenView Earnings Details
8/4/2016Q216($0.30)($0.26)$39.84 million$39.70 millionViewListenView Earnings Details
4/28/2016Q116($0.32)($0.31)$36.08 million$35.90 millionViewListenView Earnings Details
2/23/2016Q415($0.36)($0.36)$35.90 million$35.90 millionViewListenView Earnings Details
10/27/2015Q315($0.22)($0.22)$31.32 million$31.40 millionViewListenView Earnings Details
7/28/2015Q215($0.21)($0.18)$30.51 million$32.58 millionViewListenView Earnings Details
4/29/2015Q115($0.21)($0.19)$28.65 million$29.90 millionViewListenView Earnings Details
2/23/2015Q414($0.20)($0.20)$28.40 million$29.40 millionViewListenView Earnings Details
10/30/2014Q314($0.17)($0.02)$25.60 million$26.70 millionViewListenView Earnings Details
7/24/2014Q214($0.19)($0.10)$25.03 million$26.51 millionViewListenView Earnings Details
4/24/2014Q114($0.22)($0.31)$23.36 million$24.80 millionViewListenView Earnings Details
2/27/2014Q413($0.14)($0.24)$21.16 million$21.90 millionViewListenView Earnings Details
10/29/2013Q313($0.15)($0.13)$18.30 million$20.10 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.09)$19.42 million$20.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$18.63 million$19.43 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.09)($0.12)$18.46 million$18.40 millionViewListenView Earnings Details
11/1/2012Q312($0.11)($0.16)$17.29 million$16.10 millionViewN/AView Earnings Details
8/2/2012($0.07)($0.08)ViewN/AView Earnings Details
5/2/2012($0.13)($0.10)ViewN/AView Earnings Details
11/1/2011($0.07)($0.07)ViewN/AView Earnings Details
8/2/2011($0.01)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AtriCure (NASDAQ:ATRC)
Current Year EPS Consensus Estimate: $-1.100 EPS
Next Year EPS Consensus Estimate: $-0.870 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.33)($0.27)($0.30)
Q2 20162($0.31)($0.29)($0.30)
Q3 20162($0.32)($0.30)($0.31)
Q4 20162($0.34)($0.28)($0.31)
Q1 20171($0.25)($0.25)($0.25)
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)


Dividend History for AtriCure (NASDAQ:ATRC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for AtriCure (NASDAQ:ATRC)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 79.30%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2016Elizabeth D KrellDirectorSell10,000$19.73$197,300.00View SEC Filing  
9/13/2016Elizabeth D KrellDirectorSell6,000$15.93$95,580.00View SEC Filing  
8/17/2016Elizabeth D KrellDirectorSell5,000$15.20$76,000.00View SEC Filing  
3/8/2016Elizabeth D KrellDirectorSell10,000$16.91$169,100.00View SEC Filing  
12/3/2015Douglas J. SeithCOOSell5,000$21.55$107,750.00View SEC Filing  
12/2/2015Elizabeth D. KrellDirectorSell10,000$21.88$218,800.00View SEC Filing  
11/11/2015Elizabeth D. KrellDirectorSell10,000$20.68$206,800.00View SEC Filing  
4/1/2015Michael D HoovenDirectorSell142,268$20.81$2,960,597.08View SEC Filing  
3/31/2015Michael D HoovenDirectorSell20,000$20.51$410,200.00View SEC Filing  
3/30/2015Michael D HoovenDirectorSell85,000$21.01$1,785,850.00View SEC Filing  
3/13/2015Karen P RobardsDirectorSell3,150$19.53$61,519.50View SEC Filing  
3/5/2015Douglas J SeithCOOSell36,688$17.51$642,406.88View SEC Filing  
3/2/2015Elizabeth D KrellDirectorSell10,000$17.63$176,300.00View SEC Filing  
5/6/2014Douglas SeithSVPBuy1,000$15.04$15,040.00View SEC Filing  
9/13/2013Richard JohnstonInsiderSell77,610$10.00$776,100.00View SEC Filing  
8/12/2013Douglas SeithSVPBuy10,000$9.58$95,800.00View SEC Filing  
8/5/2013Richard JohnstonInsiderSell20,047$10.00$200,470.00View SEC Filing  
7/11/2013Richard M JohnstonInsiderSell2,343$10.00$23,430.00View SEC Filing  
6/19/2013Richard M JohnstonInsiderSell29,348$8.96$262,958.08View SEC Filing  
6/18/2013Richard M JohnstonInsiderSell39,682$9.18$364,280.76View SEC Filing  
6/14/2013Richard M JohnstonInsiderSell95,598$8.97$857,514.06View SEC Filing  
6/12/2013Richard M JohnstonInsiderSell35,372$9.01$318,701.72View SEC Filing  
3/6/2013James L LuckyVPSell50,065$8.14$407,529.10View SEC Filing  
9/14/2012Mark R LanningDirectorBuy11,006$7.64$84,085.84View SEC Filing  
9/13/2012Michael D HoovenDirectorBuy1,110$7.37$8,180.70View SEC Filing  
9/12/2012Michael D HoovenDirectorBuy1,150$7.10$8,165.00View SEC Filing  
9/11/2012Michael D HoovenDirectorBuy1,145$7.18$8,221.10View SEC Filing  
9/10/2012Michael D HoovenDirectorBuy1,215$7.15$8,687.25View SEC Filing  
9/7/2012Michael D HoovenDirectorBuy1,215$6.88$8,359.20View SEC Filing  
8/23/2012Karen P RobardsDirectorBuy1,000$6.70$6,700.00View SEC Filing  
8/16/2012Karen P RobardsDirectorBuy1,000$6.98$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for AtriCure (NASDAQ:ATRC)
DateHeadline logoAtriCure (ATRC) Offer Prelim. Q4 Results (NASDAQ:ATRC) - February 3 at 8:51 PM logoCORRECTING and REPLACING AtriCure to Announce Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:ATRC) - February 3 at 3:51 PM
News IconSADIF Analytics releases new summary due diligence report for AtriCure Inc ($ATRC). (NASDAQ:ATRC) - January 31 at 3:54 PM logoAtriCure to Present at the Leerink Partners Global Healthcare Conference (NASDAQ:ATRC) - January 24 at 4:10 PM logoAtriCure, Inc. – Value Analysis (NASDAQ:ATRC) : January 11, 2017 (NASDAQ:ATRC) - January 11 at 3:57 PM logoAtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : January 10, 2017 (NASDAQ:ATRC) - January 10 at 3:46 PM logoATRICURE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial (NASDAQ:ATRC) - January 9 at 4:49 PM logo8:09 am AtriCure sees Q4 revs just below consensus, provides FY17 guidance (NASDAQ:ATRC) - January 9 at 4:49 PM logoAtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016 (NASDAQ:ATRC) - January 9 at 8:05 AM logoIs Xenith Bankshares Inc (XBKS) Going To Burn These Hedge Funds? (NASDAQ:ATRC) - December 20 at 3:58 PM logoAtriCure to Present at the 35th Annual JP Morgan Healthcare Conference (NASDAQ:ATRC) - December 15 at 3:30 PM
News IconAtriCure Inc. (ATRC) Hedge Funds Are Snapping Up (NASDAQ:ATRC) - December 8 at 10:14 AM logoATRICURE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:ATRC) - November 14 at 3:51 PM logoAtriCure Names Sven Wehrwein to its Board of Directors (NASDAQ:ATRC) - November 11 at 1:04 PM logoAtriCure to Present at the Piper Jaffray 28th Annual Healthcare Conference (NASDAQ:ATRC) - November 7 at 1:34 PM logoATRICURE, INC. Financials (NASDAQ:ATRC) - November 3 at 3:31 PM logoETF’s with exposure to AtriCure, Inc. : November 2, 2016 (NASDAQ:ATRC) - November 2 at 4:01 PM logoAtriCure (ATRC): Moving Average Crossover Alert (NASDAQ:ATRC) - November 2 at 12:47 PM
News IconAtriCure Announces Approval for the cryoICE Platform in Japan (NASDAQ:ATRC) - November 1 at 3:40 PM logoAtriCure's (ATRC) cryoICE Platform Approved in Japan (NASDAQ:ATRC) - November 1 at 7:25 AM logoAtriCure Announces Approval for the cryoICE™ Platform in Japan (NASDAQ:ATRC) - November 1 at 7:25 AM logoAtriCure, Inc. :ATRC-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016 (NASDAQ:ATRC) - October 31 at 3:39 PM logoATRICURE, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:ATRC) - October 28 at 8:23 PM logoEdited Transcript of ATRC earnings conference call or presentation 27-Oct-16 8:30pm GMT (NASDAQ:ATRC) - October 28 at 8:23 PM logoUnusual 11 Mid-Day Movers 10/28: (GRVY) (VRTS) (ITGR) Higher; (OPXA) (SNMX) (STON) Lower (NASDAQ:ATRC) - October 28 at 1:19 PM logoAtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : October 28, 2016 (NASDAQ:ATRC) - October 28 at 1:19 PM logo20 Biggest Mid-Day Gainers For Friday (NASDAQ:ATRC) - October 28 at 1:00 PM logoAtriCure (NASDAQ:ATRC) - October 28 at 11:54 AM logoAtriCure Reports Third Quarter 2016 Financial Results (NASDAQ:ATRC) - October 27 at 9:12 PM logoAtriCure reports 3Q loss (NASDAQ:ATRC) - October 27 at 9:12 PM logoQ3 2016 AtriCure Inc Earnings Release - After Market Close (NASDAQ:ATRC) - October 27 at 8:05 AM logoAtriCure Announces Upcoming Investor Conference Schedule (NASDAQ:ATRC) - October 25 at 8:29 AM logoETF’s with exposure to AtriCure, Inc. : October 19, 2016 (NASDAQ:ATRC) - October 19 at 4:28 PM logoCincinnati firm just landed one of the city's largest-ever venture capital investments (NASDAQ:ATRC) - October 5 at 3:21 PM logoAtriCure to Announce Third Quarter 2016 Financial Results (NASDAQ:ATRC) - October 4 at 8:25 AM logoAtriCure, Inc. – Value Analysis (NASDAQ:ATRC) : October 3, 2016 (NASDAQ:ATRC) - October 3 at 3:33 PM logoAtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : September 30, 2016 (NASDAQ:ATRC) - September 30 at 8:53 AM logoETF’s with exposure to AtriCure, Inc. : August 31, 2016 (NASDAQ:ATRC) - August 31 at 3:37 PM logoAtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : August 30, 2016 (NASDAQ:ATRC) - August 30 at 10:14 AM logoAtriCure to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:ATRC) - August 18 at 9:05 PM logoAtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : August 15, 2016 (NASDAQ:ATRC) - August 15 at 10:51 AM logoETF’s with exposure to AtriCure, Inc. : August 11, 2016 (NASDAQ:ATRC) - August 11 at 12:52 PM logoAtriCure, Inc. :ATRC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:ATRC) - August 10 at 4:00 PM logoEdited Transcript of ATRC earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:ATRC) - August 7 at 8:17 AM
News IconAtriCure shares dip despite Street-beating Q2 (NASDAQ:ATRC) - August 5 at 9:01 PM logoNeedham & Company Cuts Price Target on AtriCure (ATRC) to $20; Reiterates Buy (NASDAQ:ATRC) - August 5 at 3:39 PM logoAtriCure Reports Second Quarter 2016 Financial Results (NASDAQ:ATRC) - August 4 at 9:24 PM logoAtriCure reports 2Q loss (NASDAQ:ATRC) - August 4 at 9:24 PM logoQ2 2016 AtriCure Inc Earnings Release - After Market Close (NASDAQ:ATRC) - August 4 at 12:09 PM logoAtriCure to Present at the Canaccord Genuity Growth Conference (NASDAQ:ATRC) - July 22 at 6:08 PM


What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Where is AtriCure's stock going? Where will AtriCure's stock price be in 2017?

7 equities research analysts have issued twelve-month price targets for AtriCure's stock. Their predictions range from $17.00 to $24.00. On average, they anticipate AtriCure's share price to reach $20.57 in the next twelve months.

When will AtriCure announce their earnings?

AtriCure is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

Who owns AtriCure stock?

AtriCure's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (14.50%), First Light Asset Management LLC (2.83%), Cortina Asset Management LLC (1.87%), State Street Corp (1.67%), Loomis Sayles & Co. L P (1.34%) and William Blair Investment Management LLC (1.32%). Company insiders that own AtriCure stock include Douglas J Seith, Elizabeth D Krell, Karen P Robards and Michael D Hooven.

Who sold AtriCure stock? Who is selling AtriCure stock?

AtriCure's stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, FMR LLC, Royce & Associates LP, Cortina Asset Management LLC, Renaissance Technologies LLC, Allianz Asset Management AG, Kopp Investment Advisors LLC and Paradigm Asset Management Co. LLC.

Who bought AtriCure stock? Who is buying AtriCure stock?

AtriCure's stock was purchased by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Axiom International Investors LLC DE, Perceptive Advisors LLC, State Street Corp, A.R.T. Advisors LLC, Two Sigma Investments LP, Tudor Investment Corp Et Al and Bayesian Capital Management LP.

How do I buy AtriCure stock?

Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of AtriCure stock cost?

One share of AtriCure stock can currently be purchased for approximately $17.39.

AtriCure (NASDAQ:ATRC) Chart for Monday, February, 20, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Earnings History Chart

Earnings by Quarter for AtriCure (NASDAQ:ATRC)

Dividend History Chart

Dividend Payments by Quarter for AtriCure (NASDAQ:ATRC)

Last Updated on 2/20/2017 by Staff